In a phase 3 study, there were clinically and statistically significant changes observed from baseline to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score for patients treated with cariprazine at 1.5 mg/day versus the placebo.
Nerivio is the first FDA-cleared smartphone-controlled prescribed wearable device for the acute treatment of migraine.
Trastuzumab deruxtecan demonstrated clinically meaningful and statistically significant improvements in overall and progression-free survival, the company says.
Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.
Results of the analysis may help inform future COVID-19 vaccine development, investigators say.
Cepacol is indicated to relieve sore throat pain.
The FDA has approved Difelikefalin injection (Korsuva; Cara Therapeutics and Vifor Pharma) for the treatment of moderate-to-severe chronic kidney disease–associated pruritus in adults undergoing hemodialysis.
Dorzolamide/timolol (Cosopt) is indicated for patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
Troy Trygstad, PharmD, PhD, MBA, executive director of CPESN USA, discussed how consumers' expectations are changing the future of pharmacy.
Any patients aged 60 years or older who does not meet risk-based recommendations can still receive hepatitis B vaccination.
Is big pharma overlooking the Goldilocks solutions right under our nose?
The approval is based on the results of the ACTIVATE and ACTIVATE-T phase 3 studies, Agios Pharmaceuticals says.
Women who get these screenings starting at aged 30 to 35 years could cut their cancer mortality by more than 50%, new study results show.
This month's OTC product news features Zinc Complex supplements, Similac 360 Total Care, and Flora Biome Live Probiotic.
Investigators used SC144, an FDA-approved molecule, to find a new pathway for a generation of nonhormonal contraceptives.
Study shows that high infliximab trough levels linked to a low risk of relapse after switching to subcutaneous infliximab in patients with inflammatory bowel disease.
Imodium provides relief of acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease.
Maribavir (Livtencity) is indicated for the treatment of adults and pediatric patients with post-transplant cytomegalovirus infection.
Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some social and cultural aspects that may contribute to hypoactive sexual desire disorder going untreated in women.
During the period in which Omicron was the dominant variant, the researchers found that fewer patients died while hospitalized compared with those admitted when the Delta variant was dominant.
Alec Smith Insulin Affordability Act provides citizens with a long-term solution to diabetes expenditures.
Experts discuss women's health and health care during the COVID-19 pandemic as part of the Pharmacy Times® Pharmacy Focus webcast series.
At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms.
Jeff Trinkl, MD, director of clinical informatics at Epic, and Caleb Cox, data scientist at Epic, explain that only about 1.8% of patients contracted COVID-19 during a hospital stay at the highest peak of cases in December 2020.
Hospital-onset clostridium difficile infections frequently occur because of both patient and environmental risk factors.
The treatment for hypertrophic cardiomyopathy met its primary endpoint at week 6 in the phase 3 VALOR-HCM trial, the pharmaceutical company says.
Beano helps prevent flatulence, abdominal bloating, and stomach pain.
Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease.
The application is based on data showing that lisocabtagene provides clinically meaningful and statistically significant improvement for those with relapsed or refractory large B-cell lymphoma.
Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.
